LOS ANGELES, CA--(Marketwired - December 14, 2016) -
| Highlighted Links |
KLH Site Info |
Stellar Biotechnologies Website |
For fiscal year 2016, the company reported a 120% increase in product sales over the previous fiscal year as it expanded its customer base and increased shipments of its Stellar KLH protein. Through its collaboration and supply agreements, Stellar KLH is now a key ingredient in multiple clinical-stage immunotherapies. During the fiscal year, the company also completed a financing round with institutional investors and extended its market opportunities through a joint venture agreement to manufacture conjugated therapeutic vaccines.
"In fiscal year 2016 we met our strategic objectives, significantly strengthened our financial position and set the stage for Stellar to continue expanding our growth opportunities. We are closely monitoring our customers' clinical trials and have a number of key objectives ahead to measure the company's progress," said Stellar President and CEO Frank Oakes. He noted that Stellar expects to move ahead with planned upgrades to its infrastructure. The company also plans to expand its commercial and clinical opportunities through new licensing, supply and research collaborations.
Stellar Chief Financial Officer Kathi Niffenegger indicated that the company would continue to prioritize the use of its working capital on manufacturing the company's Stellar KLH™ protein and related processes. "With the $6.75 million equity financing in July, we are well capitalized to advance our future infrastructure and development projects, and we remain committed to maintaining a strong balance sheet," she said.
Financial Results for the Fiscal Year Ended September 30, 2016
Total revenues increased by $0.51 million to $1.27 million for the fiscal year ended September 30, 2016 compared to $0.76 million for the fiscal year ended September 30, 2015. Product sales increased by $0.68 million to $1.24 million for fiscal year 2016 compared to $0.56 million for the prior year primarily due to an increase in product sales volume from an expanded customer base, including sales under supply agreements. The increase in product sales was partially offset by a $0.16 million reduction in contract services revenue due to the successful completion in December 2015 of services related to a two-year collaboration agreement.
Costs of sales and contract services increased by $0.24 million to $0.82 million for fiscal year 2016 compared to $0.58 million for the prior year primarily due to increased sales volumes.
Research and development expenses increased by $0.70 million to $1.73 million for fiscal year 2016 compared to $1.03 million for the prior year primarily due to increased research and development in aquaculture in the U.S. and Mexico, process development related to production and manufacturing, and product development.
General and administrative expenses increased by $0.10 million to $3.32 million for fiscal year 2016 compared to $3.23 million for the prior year primarily due to increased corporate and compensation expenses and expanded business development and investor relations activities.
Other income decreased by $1.64 million to an overall loss of $0.11 million for fiscal 2016 compared to an overall gain of $1.53 million for the prior year primarily due to a noncash change in fair value of warrant liability.
For fiscal year 2016, Stellar reported a net loss of $5.03 million, or $0.57 per basic share, compared to a net loss of $2.84 million, or $0.36 per basic share, for fiscal year 2015. The change was primarily due to significant fluctuations in non-cash gain/loss in fair value of warrant liability and non-cash foreign exchange gain/loss, as well as increased research and development expenses, which were partially offset by increased product sales.
At September 30, 2016, the company had working capital of $11.48 million. Cash, cash equivalents and short-term investments totaled $11.41 million. Stellar management estimates that expenditures for the fiscal year ending September 30, 2017 will be approximately $6.0 million.
Conference Call and Webcast Information
Stellar Biotechnologies has scheduled a conference call tomorrow, December 15, 2016 at 1:30 p.m. ET (10:30 a.m. PT), to discuss its fiscal year-end results and to provide an update on its business. To access the webcast of the conference call, go to: https://www.webcaster4.com/Webcast/Page/1359/18766. Questions for management may be submitted via the chat feature of the live online webcast. Audio of the teleconference is available by dialing (913) 312-1489. Passcode is 2812115.
An audio replay of the call will be available shortly after the conclusion of the live call, and remain available on the Stellar website for 30 days.
Stellar will file its Form 10-K for the period ending September 30, 2016 with the Securities and Exchange Commission on Wednesday, December 14, 2016. To view the Company's filings under Forms 10-K, 10-Q and 8-K, please visit the website of the Securities and Exchange Commission (www.sec.gov). To view the company's filings with the Canadian Securities Administrators ("CSA"), including the Management Discussion and Analysis and related consolidated financial statements, please visit the CSA's SEDAR website (www.sedar.com).
About Stellar Biotechnologies
Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Stellar Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.
Condensed Consolidated Statements of Operations
(Expressed in US Dollars )
One Month
Year Ended Year Ended Ended Year Ended
September 30, September 30, September 30, August 31,
2016 2015 2014 2014
------------- ------------- ------------- -----------
Revenues:
Product sales $ 1,239,689 $ 563,689 $ 32,786 $ 143,553
Contract
services
revenue 32,000 195,000 20,000 192,000
Grant revenue - - - 36,579
------------- ------------- ------------- -----------
Total Revenues 1,271,689 758,689 52,786 372,132
Expenses:
Costs of sales
and contract
services 818,566 580,824 11,636 505,728
Costs of
aquaculture 309,262 259,423 22,063 254,531
Research and
development 1,729,445 1,029,489 178,280 2,458,934
General and
administrative 3,322,772 3,227,545 293,130 2,871,455
------------- ------------- ------------- -----------
Total Expenses 6,180,045 5,097,281 505,109 6,090,648
Income (Loss) from
Operations (4,908,356) (4,338,592) (452,323) (5,718,516)
Other Income
(Loss):
Foreign exchange
gain (loss) 76,800 (653,333) (97,866) (222,437)
Increase
(decrease) in
fair value of
warrant
liability (211,956) 2,131,062 1,680,040 (2,533,305)
Other income 24,632 54,634 1,853 61,935
Income tax expense 7,200 36,800 3,800 27,200
------------- ------------- ------------- -----------
Net Income (Loss) $ (5,026,080) $ (2,843,029) $ 1,127,904 $(8,439,523)
============= ============= ============= ===========
Income (Loss) per
common share:
Basic $ (0.57) $ (0.36) $ 0.14 $ (1.11)
Diluted $ (0.57) $ (0.36) $ 0.13 $ (1.11)
Weighted average
number of common
shares
outstanding:
Basic 8,826,312 7,956,962 7,867,575 7,582,664
Diluted 8,826,312 7,956,962 8,714,045 7,582,664
Condensed Consolidated Balance Sheets
(Expressed in US Dollars )
-------------- --------------
September 30, September 30,
2016 2015
-------------- --------------
Assets:
Cash, cash equivalents and short-term
investments $ 11,405,698 $ 8,970,674
Other current assets 693,957 895,945
Noncurrent assets 838,149 519,308
-------------- --------------
Total Assets $ 12,937,804 $ 10,385,927
============== ==============
Liabilities and Shareholders' Equity:
Accounts payable, accrued liabilities and
deferred revenue $ 623,644 $ 830,018
Warrant liability, including current
portion - 1,550,630
Shareholders' equity 12,314,160 8,005,279
-------------- --------------
Total Liabilities and Shareholders'
Equity $ 12,937,804 $ 10,385,927
============== ==============
Condensed Consolidated Statements of Cash Flows
(Expressed in US Dollars )
One Month
Year Ended Year Ended Ended Year Ended
September 30, September 30, September 30, August 31,
2016 2015 2014 2014
------------- ------------- ------------- -----------
Cash Flows Used In
Operating
Activities:
Net income
(loss) $ (5,026,080) $ (2,843,029) $ 1,127,904 $(8,439,523)
Items not
affecting cash:
Depreciation
and
amortization 149,565 159,521 12,529 158,313
Share-based
payments 259,379 267,222 36,509 956,634
Foreign
exchange
(gain) loss (76,800) 653,333 97,866 222,437
Change in fair
value of
warrant
liability 211,956 (2,131,062) (1,680,040) 2,533,305
Other - - - 94,146
Changes in
working capital
items (23,649) (518,380) 108,540 207,981
------------- ------------- ------------- -----------
Net cash used in
operating
activities (4,505,629) (4,412,395) (296,692) (4,266,707)
Cash Flows
Provided By (Used
In) Investing
Activities:
Net purchases
and maturities
of short-term
investments 1,026,377 397,059 330 (5,468,815)
Net acquisition
of property,
plant and
equipment (402,271) (274,589) (13,477) (276,915)
Contribution to
joint venture (66,695) - - -
------------- ------------- ------------- -----------
Net cash provided
by (used in)
investing
activities 557,411 122,470 (13,147) (5,745,730)
Cash Flows
Provided By
Financing
Activities:
Net proceeds
from issuance
of shares 5,944,736 - - 6,479,097
Proceeds from
exercise of
warrants and
options 1,368,260 106,777 739,292 4,308,878
------------- ------------- ------------- -----------
Net cash provided
by financing
activities 7,312,996 106,777 739,292 10,787,975
Effect of exchange
rate changes on
cash and cash
equivalents 96,623 (629,808) (84,083) (212,338)
------------- ------------- ------------- -----------
Net change in cash
and cash
equivalents 3,461,401 (4,812,956) 345,370 563,200
Cash and cash
equivalents -
beginning of year 3,955,503 8,768,459 8,423,089 7,859,889
------------- ------------- ------------- -----------
Cash and cash
equivalents - end
of year $ 7,416,904 $ 3,955,503 $ 8,768,459 $ 8,423,089
============= ============= ============= ===========
